Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
icosapent ethyl + atorvastatin
- Development stage
- Discontinued
- Lead developer
- Amarin
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
AM240 (also known as AMR102) is a fixed-dose combination drug candidate developed by Amarin Corporation. It consists of icosapent ethyl, a high-purity ethyl ester of eicosapentaenoic acid (EPA), and atorvastatin, a HMG-CoA reductase inhibitor (statin). The "MCR" designation likely refers to a modified-release or multi-component release formulation designed to optimize the delivery of both active ingredients. Icosapent ethyl works by reducing hepatic very-low-density lipoprotein cholesterol (VLDL-C) synthesis and enhancing triglyceride clearance from circulating VLDL particles, while atorvastatin inhibits the rate-limiting enzyme in cholesterol biosynthesis, thereby reducing low-density lipoprotein cholesterol (LDL-C). The combination is intended for the treatment of patients with mixed dyslipidemia, aiming to simultaneously manage elevated triglyceride levels and LDL cholesterol to reduce overall cardiovascular risk.
- Other names
- icosapent ethyl + atorvastatin combinationAM240 MCRAM-240 MCRAM 240 MCR
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)PPARA (Peroxisome proliferator-activated receptor alpha)
Beyond the preview
Go deeper on icosapent ethyl + atorvastatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on icosapent ethyl + atorvastatin.